Delivery Order SPE2DB24D9802-SPE2DB26FJKTQ
- Not listed
- The Defense Logistics Agency awarded a $3,559.66 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Beyfortus 50 mg/0.5 ml syringes. The delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,496.65 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Beyfortus 50 mg/0.5 mL syringes. The delivery order, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, operates under a firm fixed-price structure with no set-aside designation, allowing DMS Pharmaceutical Group to compete directly against all...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $18,107.70 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, which runs through February 2, 2024, is for the supply of the pharmaceutical product BEYFORTUS 100 MG/ML SYRINGEML. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, holding a significant indefinite delivery contract (IDC) with the DLA under the...
- The Defense Logistics Agency awarded a delivery order valued at $2,030.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on September 17, 2025, represents a firm fixed-price purchase under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. The contract required no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $1,562.31 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This firm fixed-price delivery order, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, represents one of numerous awards made to DMS Pharmaceutical Group under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,546.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of SYFOVRE 15 mg/0.1 mL vials. The award, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $9,325.15 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued without a set-aside designation on October 20, 2025, represents one of numerous orders placed under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA. The delivery order authorizes the supply of pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain division on October 17, 2025, for VABYSMO 6 mg/0.05 ml syringes valued at $5,966.88 with a firm fixed-price structure. The delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V)...
- The Defense Logistics Agency awarded a firm-fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of BEYFORTUS 100 MG/ML SYRINGEML. The order, valued at $21,729.24, has a completion date of February 2, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with the Defense Logistics Agency, contract 4600082013 under the SPE2DB program, which has a ceiling value of up to $4,999,999 and supports...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $24,293.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on October 17, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group...
- SPE2DB24D9802Indefinite Delivery Contract
- SPE2DB24D9802-SPE2DB26FJKTQDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,834.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Beyfortus 100 mg/mL syringes. The award was issued on October 20, 2025, with an ultimate completion date of October 21, 2025, with no set-aside designation applied. DMS Pharmaceutical Group, registered in the System for Award Management since 2001, is serving as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense healthcare operations. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The IDC, awarded on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, structured as a 30-month base period with three 30-month option periods. The PPV-G GEN V represents a $30.3 billion acquisition strategy establishing multiple regional prime vendor contractors to supply comprehensive pharmaceutical products, including branded and generic medications, biologics, vaccines, and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 10/20/25 |